Why the study?
Does exposure to novel cardiovascular risk factors increase cardiovascular morbidity and mortality in healthy and high-risk subjects?
Does exposure to novel cardiovascular risk factors increase cardiovascular morbidity and mortality in healthy and high-risk subjects?
Novel risk factors beyond classical ones may play a key role in the pathogenesis of atherosclerosis and subsequent cardiovascular outcomes.
Answers are grounded in this paper and cite their sources.
Does not support routine clinical adoption of these biomarkers; leaves open their causal role and incremental value in prospective studies.
Epidemiologic studies demonstrated that the classical cardiovascular risk factors explain only a part of the increased cardiovascular morbidity and mortality. Large scale studies have shown that novel cardiovascular risk factors, including increased plasma homocysteine, fibrinogen, C-reactive protein, uric acid levels, and increased white blood cells count as well as low adiponectin levels, might have a key role in the pathogenesis of the cardiovascular disease. This review examines recent literature data on the effect of novel risk factors on cardiovascular morbidity and mortality in healthy subjects as well as in subjects at high cardiovascular risk. In addition, the pathogenetic mechanisms linking the effects of the novel risk factors with atherosclerosis are discussed.
No takes yet. Share an insight, caveat, or question.
Papazafiropoulou et al. (2008) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: